Literature DB >> 2969819

Rearrangement and expression of T cell receptor and immunoglobulin loci in immortalized CD4-CD8- T cell lines.

D Primi1, R A Clynes, E Jouvin-Marche, J P Marolleau, E Barbier, P A Cazenave, K B Marcu.   

Abstract

Injection of newborn mice with mixtures of wild-type moloney murine leukemia (Mo-MuLV) virus and other recombinant retroviruses harboring the myc oncogene alone or in combination with the H-ras oncogene resulted in a 100% incidence of lymphatic leukemias from which permanent cell lines could be established in vitro. These cells are immunoglobulin (Ig)-, Thy-1+BP- and CD8-CD4- indicating that they are early thymocytes. Such transformed pre-T lines lack retroviral myc and ras genes but occasionally possess proviral insertion near to their endogenous myc and pim genes. We show that both Ig heavy chain (Igh) and T cell receptor (TcR) genes are rearranged in most of these lines. In some cases, a primary recombination was followed by a secondary rearrangement at the same locus. We show that VT gamma genes can rearrange outside of their known cluster suggesting that TcR gamma diversification in such pre-T cells may be different to that in more mature T cells. Ig D-JH recombinations may precede TcR gene recombination in these early T cell lines, and some but not all express sterile Cmu transcripts. Some of these lines express surface heterodimers that appear composed of alpha and beta chains that can be immunoprecipitated with a monoclonal anti-T3 antibody but not with the anti-V beta 8 monoclonal antibody F23.1. This established pre-T cell line represents novel biological material for the dissection of T cell development and function analogous to A-MuLV transformed pre-B cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969819     DOI: 10.1002/eji.1830180720

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Transcription of germ line V alpha segments correlates with ongoing T-cell receptor alpha-chain rearrangement.

Authors:  J D Fondell; K B Marcu
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

2.  Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing.

Authors:  Diana Bellavia; Marco Mecarozzi; Antonio F Campese; Paola Grazioli; Claudio Talora; Luigi Frati; Alberto Gulino; Isabella Screpanti
Journal:  EMBO J       Date:  2007-03-01       Impact factor: 11.598

3.  Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma.

Authors:  Claudio Talora; Antonio F Campese; Diana Bellavia; Monica Pascucci; Saula Checquolo; Manuela Groppioni; Luigi Frati; Harald von Boehmer; Alberto Gulino; Isabella Screpanti
Journal:  EMBO Rep       Date:  2003-10-17       Impact factor: 8.807

4.  Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.

Authors:  V Kumar; R Palermo; C Talora; A F Campese; S Checquolo; D Bellavia; L Tottone; G Testa; E Miele; S Indraccolo; A Amadori; E Ferretti; A Gulino; A Vacca; I Screpanti
Journal:  Leukemia       Date:  2014-04-14       Impact factor: 11.528

5.  Genomic organization of the mouse T cell receptor V alpha family.

Authors:  E Jouvin-Marche; I Hue; P N Marche; C Liebe-Gris; J P Marolleau; B Malissen; P A Cazenave; M Malissen
Journal:  EMBO J       Date:  1990-07       Impact factor: 11.598

6.  Epithelial V-like antigen (EVA), a novel member of the immunoglobulin superfamily, expressed in embryonic epithelia with a potential role as homotypic adhesion molecule in thymus histogenesis.

Authors:  M Guttinger; F Sutti; M Panigada; S Porcellini; B Merati; M Mariani; T Teesalu; G G Consalez; F Grassi
Journal:  J Cell Biol       Date:  1998-05-18       Impact factor: 10.539

7.  Constitutive endocytosis and degradation of the pre-T cell receptor.

Authors:  Maddalena Panigada; Simona Porcellini; Eliane Barbier; Sonja Hoeflinger; Pierre-André Cazenave; Hua Gu; Hamid Band; Harald von Boehmer; Fabio Grassi
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.